Friday, May 11, 2018

News Recap:

CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF).

This Common Viral Disease Has Plagued Humanity Thousands of Years Longer Than We Thought. Evidence of Hepatitis B has been found in human DNA dating back to the Bronze Age, around 4,500 years ago. We now have proof that it infected humans broadly across Eurasia for millennia, pushing back the earliest evidence we have by thousands of years. Previously, the earliest evidence of Hepatitis B was just 450 years

Biologic Psoriasis Therapies Pose Limited Risk for Hepatitis B Reactivation. A recent systematic review of the literature has confirmed that biologic therapies can reactivate hepatitis B virus (HBV) in patients with plaque psoriasis. Although the study found that any prior HBV exposure was associated with the risk for viral reactivation, patients with chronic HBV were far more likely to experience reactivation than those with evidence of HBV exposure but without hepatitis.

Not Again!!:
Er Nurse Could Have Exposed Thousands of Patients to Hepatitis C Infection, Officials Warn. Officials are urging thousands of patients treated at a hospital in the State of Washington to get tested for Hepatitis C, amid fears two patients contracted the disease from a nurse working in the emergency department. The MultiCare Good Samaritan Hospital in Puyallup, Washington, warned in a safety alert statement that patients who were treated at the ER between August 4, 2017 and March 23, 2018 could have been exposed to the disease.